Advertisement

Pegylated-Liposomal Doxorubicin (Doxil®) in the Treatment of AIDS-Related Kaposi’s Sarcoma

  • Donald W. Northfelt
Part of the Biotechnology Intelligence Unit book series (BIOIU)

Abstract

In 1981 reports of the development of Kaposi’s sarcoma in previously healthy young homosexual men heralded the onset of the epidemic of acquired immunodeficiency syndrome (AIDS). 1–3 Kaposi’s sarcoma is the most common neoplasm in persons infected with the human immunodeficiency virus (HIV), having been the initial (“AIDS-defining”) diagnosis in 15% of the patients with AIDS in the United States.4 It has been estimated that AIDS-related Kaposi’s sarcoma (AIDS-KS) has a prevalence of about 20,000 cases in this country.5 While the overall incidence seems to be declining, the actual morbidity and mortality ascribed to AIDS-KS has increased, probably as a result of improved therapy of opportunistic infections without concurrent improvements in the treatment of AIDS-KS.6,7 Several modalities have been employed successfully to treat AIDS-KS, but their toxicities, as well as the patients’ underlying immunodeficiency, have limited their usefulness. Also, AIDS-KS produces visceral involvement, especially in the lungs, for which current treatments are less effective than for cutaneous disease. 8,9

Keywords

Liposomal Doxorubicin Experience Disease Progression Indicator Lesion Doxorubicin Therapy Advanced Human Immunodeficiency Virus Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Friedman-Kein A, Laubenstein L, Marmor M et al. Kaposi’s sarcom and pneumocystic pneumonia among homosexual men-New York City and California. MMWR 1981; 30: 305–308.Google Scholar
  2. 2.
    Hymes KB, Cheung TL, Green JB et al. Kaposi’s sarcoma in homosexual men: a report of 8 cases. Lancet 1981; 2: 598–600.PubMedCrossRefGoogle Scholar
  3. 3.
    Masur H, Michilis MA, Green JB et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestations of cellular immune dysfunction. N Engl J Med 1981; 30: 51431–1438.Google Scholar
  4. 4.
    Beral V, Peterman TA, Berkelman RL et al. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 1: 123–128.CrossRefGoogle Scholar
  5. 5.
    Northfelt DW. AIDS-related Kaposi’s sarcoma: still a problem, still an opportunity. J Clin Oncol 1994; 12: 1109–1110.PubMedGoogle Scholar
  6. 6.
    Peters BS, Beck EJ, Coleman DG et al. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. Br J Med 1991; 302: 203–207.CrossRefGoogle Scholar
  7. 7.
    Selik RM, Chu SY, Ward JW. Trends in infectious disease and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995; 123:933–936.Google Scholar
  8. 8.
    Gill PS, Akil B, Colletti P et al. Pulmonary Kaposi’s sarcoma: clinical findings and results of therapy. Am J Med 1989; 87: 57–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaplan LD, Hopewell PC, Jaffe H et al. Kaposi’s sarcoma involving the lung in patients with acquired immunodeficiency syndrome. J Acquir Immune Defic Synd 1988; 1: 23–30.Google Scholar
  10. 10.
    Centers for Disease Control. Epidemiologic aspects of the current outbreak of Kaposi’s sarcoma and opportunistic infections. N Engl J Med1982: 306: 248–252.Google Scholar
  11. 11.
    Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph 1872; 4: 265–273.Google Scholar
  12. 12.
    Taylor JF, Templeton AC, Vogel CL et al. Kaposi’s sarcoma in Uganda: a clinicopathological study. Int J Cancer 1971; 3: 122–135.CrossRefGoogle Scholar
  13. 13.
    Harwood AR, Osoba D, Hofstader SL et al. Kaposi’s sarcoma in recipients of renal transplants. Am J Med 1979; 67: 759–765.PubMedCrossRefGoogle Scholar
  14. 14.
    Penn I. Tumors of the immunocompromised patient. Ann Rev Med 1988; 39: 63–73.PubMedCrossRefGoogle Scholar
  15. 15.
    Lemp GF, Payne SF, Neal D et al. Survival trends for patients with AIDS. JAMA 1990; 263: 402–406.PubMedCrossRefGoogle Scholar
  16. 16.
    Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and those without HIV infection. N Engl J Med 1995; 332; 1181–1185.PubMedCrossRefGoogle Scholar
  17. 17.
    Northfelt DW. Treatment of Kaposi’s sarcoma: current guidelines and future perspectives. Drugs 1994; 48: 569–582.PubMedCrossRefGoogle Scholar
  18. 18.
    Gill PS, Rarick M, McCutchan JA et al. Systemic treatment of AIDS-related Kaposi’s sarcoma: results of a randomized trial. Am J Med 1991; 90: 427–433.PubMedGoogle Scholar
  19. 19.
    Gabizon A, Chisin R, Amselem S et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated Adriamycin. Br J Cancer 1991; 64: 1125–1132.PubMedCrossRefGoogle Scholar
  20. 20.
    Gabizon AA, Barenholz Y, Bialer M. Prolongation of circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharmaceut Res 1993; 10:703–708.Google Scholar
  21. 21.
    Huang SK, Mahew E, Gilani S. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774–6781.PubMedGoogle Scholar
  22. 22.
    Huang SK, Martin FJ, Jay G et al. Extravasation and transcytosis of liposomes in Kaposi’s sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 1993; 143: 10–14.PubMedGoogle Scholar
  23. 23.
    Vaage J, Barbera-Guillem E, Abra R et al. Tissue distributions and therapeutic effects of intravenous free and liposomal doxorubicin against human prostatic carcinoma xenografts. Cancer 1994; 73: 147H - 1484.Google Scholar
  24. 24.
    Northfelt DW, Martin FJ, Working P et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996; 36: 55–63.PubMedCrossRefGoogle Scholar
  25. 25.
    Northfelt DW. Stealth® liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-Kaposi’s sarcoma (AIDS-KS) lesions than to normal skin. Proc ASCO 1994; abstract 5.Google Scholar
  26. 26.
    Hengge UR, Brockmeyer NH, Baumann M et al. Liposomal doxorubicin in AIDS-related Kaposi’s sarcoma. Lancet 1993; 342: 497.PubMedCrossRefGoogle Scholar
  27. 27.
    Simpson JK, Miller RF, Spittle MF. Liposomal doxorubicin for treatment of AIDS-related Kaposi’s sarcoma. Clin Oncol 1993; 5: 372–374.CrossRefGoogle Scholar
  28. 28.
    Bogner JR, Kronawitter U, Rolinski B et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Synd 1994; 7: 463–468.Google Scholar
  29. 29.
    James ND, Coker RJ, Tomlinson D et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi’s sarcoma in AIDS. Clin Oncol 1994; 6: 294–296.CrossRefGoogle Scholar
  30. 30.
    Sturzl M, Zeitz C, Eisenburg B et al. Liposomal doxorubicin in the treatment of AIDS-associated Kaposi’s sarcoma: clinical, histological and cell biological evaluation. Res Virol 1994; 145: 261–269.PubMedCrossRefGoogle Scholar
  31. 31.
    Wagner D, Kern WV, Kern P. Liposomal doxorubicin in AIDS-related Kaposi’s sarcoma: long-term experiences. Clin Investig 1994; 72: 417–423.PubMedGoogle Scholar
  32. 32.
    Harrison M, Tomlinson D, Stewart S. Liposome-entrapped doxorubicin: an active agent in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1995; 13: 914–920.PubMedGoogle Scholar
  33. 33.
    Northfelt DW, Dezube BJ, Thommes JA et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15: 653–659.PubMedGoogle Scholar
  34. 34.
    Krown SE, Metroka C, Wernz JC. Kaposi’s sarcoma in the acquired immunodeficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989; 7: 201–1207.Google Scholar
  35. 35.
    Fischl MA, Krown SE, O’Boyle KP et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi’s sarcoma. J Acquir Immun Defic Synd 1993; 6: 259–264.Google Scholar
  36. 36.
    Gill P, Rarick M, Bernstein-Singer M et al. Treatment of advanced Kaposi’s sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 1990; 13: 315–319.PubMedCrossRefGoogle Scholar
  37. 37.
    Rarick MU, Gill PS, Montgomery T et al. Treatment of epidemic Kaposi’s sarcoma with combination chemotherapy (vincristine and bleomycin) and zidovudine. Ann Oncol 1990; 1: 147–149.PubMedGoogle Scholar
  38. 38.
    Northfelt DW, Dezube BJ, Thommes JA et al. Randomized comparative trial of Doxil* vs. Adriamycin, bleomycin, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi’s sarcoma (AIDS-KS). 3rd Conference on Retroviruses and Opportunistic Infections 1996; abstract 379.Google Scholar
  39. 39.
    Stewart S, Jablonowski H, Goebel FD et al. Randomized comparative trial of Doxil° vs. bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. XI International Conference on AIDS 1996; abstract LB.B.6026.Google Scholar
  40. 40.
    Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin. JNCI 1995; 87: 1556–1557.PubMedCrossRefGoogle Scholar
  41. 41.
    Berry G, Billingham M, Alderman E et al. Reduced cardiotoxicity of Doxil (pegylated liposomal doxorubicin) in AIDS Kaposi’s sarcoma patients compared to a matched control group of cancer patients given doxorubicin. Proc ASCO 1996; abstract 843.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Donald W. Northfelt

There are no affiliations available

Personalised recommendations